Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine

Hiroyuki Kobayashi; Hiroaki Takeda; Hidehiro Watanabe; Hiroshi Ohtami; Susumu Sakayori; Akira Saito; Ichiro Nakayama; Kiyoshi Sato; Masumi Tomizawa; Yohmei Hiraga; Mitsuhide Ohmichi; Kazuo Takebe; Seiichi Murakami; Mitsuo Masuda; Kenichi Imamura; Hisashi Nakahata; Miyoko Saito; Takeshi Osonoi; Masashi Tamura; Kazuki Konishi; Kazuo Obara; Taro Chiba; Yoji Aoyama; Akiko Shiba; Akira Watanabe; Kazunao Niizuma; Shigeo Takizawa; Yushi Nakai; Yoshihiro Honda; Masataka Katsu; Akira Ohishi; Morio Nakamura; Kotaro Kaneko; Michihiro Sakauchi; Noboru Aosaki; Kaoru Shimada; Hajime Goto; Mieko Goto; Yasuyuki Sano; Yasufumi Miyamoto; Yasuo Arai; Norio Kikuchi; Osamu Sakai; Koya Shiba; Masaki Yoshida; Seiji Hori; Jingoro Shimada; Kihachiro Shimizu; Koichiro Nakata; Tatsuo Nakatani; Eiyasu Tsuboi; Koji Narui; Yoshitaka Nakamori; Hiroko Inagawa; Kyoichi Totsuka; Yusuke Shibata; Ken Kikuchi; Hiromi Hasegawa; Takeshi Mori; Hiroshi Isonuma; Mayumi Takahashi; Tsukasa Ebe; Masayoshi Inagaki; Otohiko Kunii; Atsuko Guji; Isao Ohyatsu; Yasuo Ono; Taku Miyashita; Hajime Nishiya; Yasumasa Tokumura; Hajime Sugiyama; Morimichi Yamaguchi; Masumi Aoki; Toshiaki Haga; Hideo Miyashita; Yasuo Ikeda; Masahiro Kisaki; Shigehisa Mori; Hiroshi Uchida; Yoshio Kobayashi; Koichiro Kudo; Tadashi Horiuchi; Shunsuke Shoji; Junzaburo Kabe; Harumi Shishido; Hideaki Nagai; Koji Satoh; Atsuyuki Kurashima; Shuji Miyake; Kenji Kawakami; Koji Hayashi; Fumio Matumoto; Takeo Imai; Iwao Sakurai; Koji Yoshikawa; Takayuki Takahashi; Masayuki Morita; Shigeki Odagiri; Kaneo Suzuki; Hiroshi Takahashi; Kenichi Takahashi; Takao Okubo; Hirotada Ikeda; Tamotsu Kaneko; Masaaki Arakawa; Nobuki Aoki; Osamu Sekine; Yasutoshi Suzuki; Katsuji Uno; Motohiro Yagi; Hajimu Takeda; Saburo Izumi; Atsuhiko Sato; Kingo Senda; Takafumi Suda; Ryoji Tamura; Atsushi Yoshitomi; Takeshi Yagi; Toshihiko Takeuchi; Yasuo Yamada; Atsushi Nakamura; Toshinobu Yamamoto; Kazuhide Yamamoto; Hidekazu Hanaki; Toshiyuki Yamamoto; Toru Matsuura; Masahiro Yamagoshi; Kanzo Suzuki; Kaoru Shimokata; Satoshi Ichiyama; Hidehiko Saito; Shuzo Sakai; Shiro Nomura; Kazuyoshi Senda; Takeshi Iwahara; Hironobu Minami; Masashi Yamamoto; Hiroshi Saito; Sadaaki Yamori; Tomohisa Shibagaki; Keisuke Nishiwaki; Kazuo Nakanishi; Nobuhiro Narita; Keiichi Mikasa; Masayoshi Sawaki; Mitsuru Konishi; Koichi Maeda; Kaoru Hamada; Shoji Takeuchi; Masahiro Sakamoto; Masayuki Tsujimoto; Mikikazu Kunimatsu; Fumiyuki Kuze; Mitsuru Kawai; Fumio Miki; Yoshiyasu Ikuno; Akihito Murata; Kazuo Sakamoto; Masato Hiruma; Shinichiro Otani; Yasushi Hara; Koji Nakayama; Satohiko Tanaka; Akihisa Hanatani; Saburo Yano; Masaru Nakagawa; Rinzo Soejima; Niro Okimoto; Osamu Moriya; Yoshihito Niki; Toshiharu Matsushima; Makoto Kimura; Yoshihiro Kobashi; Norifumi Adachi; Jun Tanabe; Yoshihiko Tano; Hiroki Hara; Michio Yamakido; Kenji Hasegawa; Tsuyoshi Ogura; Kanji Asada; Osamu Namikawa; Shinsuke Nishioka; Masahiko Azuma; Mikie Maeda; Minoru Shirakami; Yoshiyuki Niho; Yoshiro Sawae; Kaoru Okada; Koji Takaki; Nobuyuki Shimono; Hiroyasu Misumi; Katsuhiko Eguchi; Kotaro Oizumi; Naoto Tokunaga; Yoichiro Ichikawa; Takafumi Yano; Kohei Hara; Shigeru Kohno; Hironobu Koga; Mitsuo Kaku; Kazunori Tomono; Naomi Ito; Koichi Watanabe; Keizo Matsumoto; Masakazu Takasugi; Mikio Taguchi; Kazunori Oishi; Atsushi Takahashi; Hiroshi Watanabe; Akemi Omori; Kiwao Watanabe; Tsuyoshi Nagatake; Hirofumi Tanaka; Soichiro Yamauchi; Tomoku Ichimiya; Kazufumi Hirai; Hiroshi Kawano; Takayoshi Tashiro; Kiyoshi Shima; Shinobu Takenaka; Atsushi Saito; Hiroshi Fukuhara; Yuei Irabu; Jun Inadome; Nobuchika Kusano; Yoshiko Furugen; Isamu Nakasone; Shinko Taira

doi:10.11250/chemotherapy1995.43.Supplement1_333

Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine

Hiroyuki Kobayashi, Hiroaki Takeda, Hidehiro Watanabe, Hiroshi Ohtami, Susumu Sakayori, Akira Saito, Ichiro Nakayama, Kiyoshi Sato, Masumi Tomizawa, Yohmei Hiraga, Mitsuhide Ohmichi, Kazuo Takebe, Seiichi Murakami, Mitsuo Masuda, Kenichi Imamura, Hisashi Nakahata, Miyoko Saito, Takeshi Osonoi, Masashi Tamura, Kazuki KonishiKazuo Obara, Taro Chiba, Yoji Aoyama, Akiko Shiba, Akira Watanabe, Kazunao Niizuma, Shigeo Takizawa, Yushi Nakai, Yoshihiro Honda, Masataka Katsu, Akira Ohishi, Morio Nakamura, Kotaro Kaneko, Michihiro Sakauchi, Noboru Aosaki, Kaoru Shimada, Hajime Goto, Mieko Goto, Yasuyuki Sano, Yasufumi Miyamoto, Yasuo Arai, Norio Kikuchi, Osamu Sakai, Koya Shiba, Masaki Yoshida, Seiji Hori, Jingoro Shimada, Kihachiro Shimizu, Koichiro Nakata, Tatsuo Nakatani, Eiyasu Tsuboi, Koji Narui, Yoshitaka Nakamori, Hiroko Inagawa, Kyoichi Totsuka, Yusuke Shibata, Ken Kikuchi, Hiromi Hasegawa, Takeshi Mori, Hiroshi Isonuma, Mayumi Takahashi, Tsukasa Ebe, Masayoshi Inagaki, Otohiko Kunii, Atsuko Guji, Isao Ohyatsu, Yasuo Ono, Taku Miyashita, Hajime Nishiya, Yasumasa Tokumura, Hajime Sugiyama, Morimichi Yamaguchi, Masumi Aoki, Toshiaki Haga, Hideo Miyashita, Yasuo Ikeda, Masahiro Kisaki, Shigehisa Mori, Hiroshi Uchida, Yoshio Kobayashi, Koichiro Kudo, Tadashi Horiuchi, Shunsuke Shoji, Junzaburo Kabe, Harumi Shishido, Hideaki Nagai, Koji Satoh, Atsuyuki Kurashima, Shuji Miyake, Kenji Kawakami, Koji Hayashi, Fumio Matumoto, Takeo Imai, Iwao Sakurai, Koji Yoshikawa, Takayuki Takahashi, Masayuki Morita, Shigeki Odagiri, Kaneo Suzuki, Hiroshi Takahashi, Kenichi Takahashi, Takao Okubo, Hirotada Ikeda, Tamotsu Kaneko, Masaaki Arakawa, Nobuki Aoki, Osamu Sekine, Yasutoshi Suzuki, Katsuji Uno, Motohiro Yagi, Hajimu Takeda, Saburo Izumi, Atsuhiko Sato, Kingo Senda, Takafumi Suda, Ryoji Tamura, Atsushi Yoshitomi, Takeshi Yagi, Toshihiko Takeuchi, Yasuo Yamada, Atsushi Nakamura, Toshinobu Yamamoto, Kazuhide Yamamoto, Hidekazu Hanaki, Toshiyuki Yamamoto, Toru Matsuura, Masahiro Yamagoshi, Kanzo Suzuki, Kaoru Shimokata, Satoshi Ichiyama, Hidehiko Saito, Shuzo Sakai, Shiro Nomura, Kazuyoshi Senda, Takeshi Iwahara, Hironobu Minami, Masashi Yamamoto, Hiroshi Saito, Sadaaki Yamori, Tomohisa Shibagaki, Keisuke Nishiwaki, Kazuo Nakanishi, Nobuhiro Narita, Keiichi Mikasa, Masayoshi Sawaki, Mitsuru Konishi, Koichi Maeda, Kaoru Hamada, Shoji Takeuchi, Masahiro Sakamoto, Masayuki Tsujimoto, Mikikazu Kunimatsu, Fumiyuki Kuze, Mitsuru Kawai, Fumio Miki, Yoshiyasu Ikuno, Akihito Murata, Kazuo Sakamoto, Masato Hiruma, Shinichiro Otani, Yasushi Hara, Koji Nakayama, Satohiko Tanaka, Akihisa Hanatani, Saburo Yano, Masaru Nakagawa, Rinzo Soejima, Niro Okimoto, Osamu Moriya, Yoshihito Niki, Toshiharu Matsushima, Makoto Kimura, Yoshihiro Kobashi, Norifumi Adachi, Jun Tanabe, Yoshihiko Tano, Hiroki Hara, Michio Yamakido, Kenji Hasegawa, Tsuyoshi Ogura, Kanji Asada, Osamu Namikawa, Shinsuke Nishioka, Masahiko Azuma, Mikie Maeda, Minoru Shirakami, Yoshiyuki Niho, Yoshiro Sawae, Kaoru Okada, Koji Takaki, Nobuyuki Shimono, Hiroyasu Misumi, Katsuhiko Eguchi, Kotaro Oizumi, Naoto Tokunaga, Yoichiro Ichikawa, Takafumi Yano, Kohei Hara, Shigeru Kohno, Hironobu Koga, Mitsuo Kaku, Kazunori Tomono, Naomi Ito, Koichi Watanabe, Keizo Matsumoto, Masakazu Takasugi, Mikio Taguchi, Kazunori Oishi, Atsushi Takahashi, Hiroshi Watanabe, Akemi Omori, Kiwao Watanabe, Tsuyoshi Nagatake, Hirofumi Tanaka, Soichiro Yamauchi, Tomoku Ichimiya, Kazufumi Hirai, Hiroshi Kawano, Takayoshi Tashiro, Kiyoshi Shima, Shinobu Takenaka, Atsushi Saito, Hiroshi Fukuhara, Yuei Irabu, Jun Inadome, Nobuchika Kusano, Yoshiko Furugen, Isamu Nakasone, Shinko Taira

General Internal Medicine

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine. The clinical usefulness of grepafloxacin (GPFX), a new quinolone synthesized as an oral antibacterial agent, in various infections in the field of internal medicine was investigated by collaborative research at 62 institutions nationwide. GPFX was administered primarily to patients with respiratory tract infections (RTI), mostly at daily doses of 100~300 mg once or in 2 divided doses. Clinical efficacy was evaluated in 509 of a total of 525 patients for analysis and efficacy was observed in 443 (87.0%) of the 509, including 432 (87.1%) of 496 patients with RTI and 11 (84.6%) of 13 patients with urinary tract infections (UTI). In RTI by disease, clinical efficacy was observed in 19 (86.4%) of 22 patients with pharyngolaryngitis or pharyngitis, 17 (94.4%) of 18 with tonsillitis, 53 (91.4%) of 58 with acute bronchitis, 104 (87.4%) of 119 with pneumonia, 17 (89.5%) of 19 with mycoplasmal pneumonia, 5 (100%) of 5 with atypical pneumonia, 117 (87.3%) of 133 with chronic bronchitis, 48 of 63 with bronchiectasis, 17 (89.5%) of 19 with diffuse panbronchiolitis, and 35 (87.5%) of 40 with secondary infection with chronic respiratory disease. Bacteriological efficacy in RTI was evaluated in 233 patients. Bacteriological eradication was observed in 154 (78.2%) of 197 patients with monomicrobial infection and 22 (61.1%) of 36 with polymicrobial infection. For monomicrobial infection, bacteriological efficacy was higher in patients infected with gram-positive bacteria (48 of 53, 90.6%) than in patients infected with gram-negative bacteria (105 of 142, 73.9%). The MIC80 of GPFX was 0.39 μg/ml in 115 strains of causative organisms in which the MIC80 was determined in RTI, and the MIC80 of norfloxacin (NFLX), ofloxacin (0FLX), enoxacin (ENX) and ciprofloxacin (CPFX) were 6.25, 1.56, 6.25 and 0.78 μg/ml, respectively, in 97 strains. Adverse drug reactions were observed in 26 (5.0%, 38 cases) of 519 patients, including mostly gastrointestinal symptoms, CNS symptoms and hypersensitive symptoms. Abnormal clinical laboratory test values were observed in 49 (10.0%) of 490 patients. Major changes included increased eosinophil and transaminase. None of the reported symptoms or abnormal changes were serious. Based on clinical efficacy, adverse drug reactions and abnormal clinical laboratory test values, GPFX was judged to be useful in 432 (84.7%) of a total of 510 patients, 422 (84.9%) of 497 with RTI and 10 (76.9%) of 13 with UTI. From these results, GPFX was considered to be useful in the treatment of various infectious diseases, particularly RTI, in the field of internal medicine.

Original language	English
Pages (from-to)	333-351
Number of pages	19
Journal	Japanese Journal of Chemotherapy
Volume	43
DOIs	https://doi.org/10.11250/chemotherapy1995.43.Supplement1_333
Publication status	Published - 1995

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1995.43.Supplement1_333

Cite this

Kobayashi, H., Takeda, H., Watanabe, H., Ohtami, H., Sakayori, S., Saito, A., Nakayama, I., Sato, K., Tomizawa, M., Hiraga, Y., Ohmichi, M., Takebe, K., Murakami, S., Masuda, M., Imamura, K., Nakahata, H., Saito, M., Osonoi, T., Tamura, M., ... Taira, S. (1995). Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine. Japanese Journal of Chemotherapy, 43, 333-351. https://doi.org/10.11250/chemotherapy1995.43.Supplement1_333

Kobayashi, H, Takeda, H, Watanabe, H, Ohtami, H, Sakayori, S, Saito, A, Nakayama, I, Sato, K, Tomizawa, M, Hiraga, Y, Ohmichi, M, Takebe, K, Murakami, S, Masuda, M, Imamura, K, Nakahata, H, Saito, M, Osonoi, T, Tamura, M, Konishi, K, Obara, K, Chiba, T, Aoyama, Y, Shiba, A, Watanabe, A, Niizuma, K, Takizawa, S, Nakai, Y, Honda, Y, Katsu, M, Ohishi, A, Nakamura, M, Kaneko, K, Sakauchi, M, Aosaki, N, Shimada, K, Goto, H, Goto, M, Sano, Y, Miyamoto, Y, Arai, Y, Kikuchi, N, Sakai, O, Shiba, K, Yoshida, M, Hori, S, Shimada, J, Shimizu, K, Nakata, K, Nakatani, T, Tsuboi, E, Narui, K, Nakamori, Y, Inagawa, H, Totsuka, K, Shibata, Y, Kikuchi, K, Hasegawa, H, Mori, T, Isonuma, H, Takahashi, M, Ebe, T, Inagaki, M, Kunii, O, Guji, A, Ohyatsu, I, Ono, Y, Miyashita, T, Nishiya, H, Tokumura, Y, Sugiyama, H, Yamaguchi, M, Aoki, M, Haga, T, Miyashita, H, Ikeda, Y, Kisaki, M, Mori, S, Uchida, H, Kobayashi, Y, Kudo, K, Horiuchi, T, Shoji, S, Kabe, J, Shishido, H, Nagai, H, Satoh, K, Kurashima, A, Miyake, S, Kawakami, K, Hayashi, K, Matumoto, F, Imai, T, Sakurai, I, Yoshikawa, K, Takahashi, T, Morita, M, Odagiri, S, Suzuki, K, Takahashi, H, Takahashi, K, Okubo, T, Ikeda, H, Kaneko, T, Arakawa, M, Aoki, N, Sekine, O, Suzuki, Y, Uno, K, Yagi, M, Takeda, H, Izumi, S, Sato, A, Senda, K, Suda, T, Tamura, R, Yoshitomi, A, Yagi, T, Takeuchi, T, Yamada, Y, Nakamura, A, Yamamoto, T, Yamamoto, K, Hanaki, H, Yamamoto, T, Matsuura, T, Yamagoshi, M, Suzuki, K, Shimokata, K, Ichiyama, S, Saito, H, Sakai, S, Nomura, S, Senda, K, Iwahara, T, Minami, H, Yamamoto, M, Saito, H, Yamori, S, Shibagaki, T, Nishiwaki, K, Nakanishi, K, Narita, N, Mikasa, K, Sawaki, M, Konishi, M, Maeda, K, Hamada, K, Takeuchi, S, Sakamoto, M, Tsujimoto, M, Kunimatsu, M, Kuze, F, Kawai, M, Miki, F, Ikuno, Y, Murata, A, Sakamoto, K, Hiruma, M, Otani, S, Hara, Y, Nakayama, K, Tanaka, S, Hanatani, A, Yano, S, Nakagawa, M, Soejima, R, Okimoto, N, Moriya, O, Niki, Y, Matsushima, T, Kimura, M, Kobashi, Y, Adachi, N, Tanabe, J, Tano, Y, Hara, H, Yamakido, M, Hasegawa, K, Ogura, T, Asada, K, Namikawa, O, Nishioka, S, Azuma, M, Maeda, M, Shirakami, M, Niho, Y, Sawae, Y, Okada, K, Takaki, K, Shimono, N, Misumi, H, Eguchi, K, Oizumi, K, Tokunaga, N, Ichikawa, Y, Yano, T, Hara, K, Kohno, S, Koga, H, Kaku, M, Tomono, K, Ito, N, Watanabe, K, Matsumoto, K, Takasugi, M, Taguchi, M, Oishi, K, Takahashi, A, Watanabe, H, Omori, A, Watanabe, K, Nagatake, T, Tanaka, H, Yamauchi, S, Ichimiya, T, Hirai, K, Kawano, H, Tashiro, T, Shima, K, Takenaka, S, Saito, A, Fukuhara, H, Irabu, Y, Inadome, J, Kusano, N, Furugen, Y, Nakasone, I & Taira, S 1995, 'Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine', Japanese Journal of Chemotherapy, vol. 43, pp. 333-351. https://doi.org/10.11250/chemotherapy1995.43.Supplement1_333

@article{7c68bcc7d44f480399cffe5199b8aa04,

title = "Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine",

abstract = "Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine. The clinical usefulness of grepafloxacin (GPFX), a new quinolone synthesized as an oral antibacterial agent, in various infections in the field of internal medicine was investigated by collaborative research at 62 institutions nationwide. GPFX was administered primarily to patients with respiratory tract infections (RTI), mostly at daily doses of 100~300 mg once or in 2 divided doses. Clinical efficacy was evaluated in 509 of a total of 525 patients for analysis and efficacy was observed in 443 (87.0%) of the 509, including 432 (87.1%) of 496 patients with RTI and 11 (84.6%) of 13 patients with urinary tract infections (UTI). In RTI by disease, clinical efficacy was observed in 19 (86.4%) of 22 patients with pharyngolaryngitis or pharyngitis, 17 (94.4%) of 18 with tonsillitis, 53 (91.4%) of 58 with acute bronchitis, 104 (87.4%) of 119 with pneumonia, 17 (89.5%) of 19 with mycoplasmal pneumonia, 5 (100%) of 5 with atypical pneumonia, 117 (87.3%) of 133 with chronic bronchitis, 48 of 63 with bronchiectasis, 17 (89.5%) of 19 with diffuse panbronchiolitis, and 35 (87.5%) of 40 with secondary infection with chronic respiratory disease. Bacteriological efficacy in RTI was evaluated in 233 patients. Bacteriological eradication was observed in 154 (78.2%) of 197 patients with monomicrobial infection and 22 (61.1%) of 36 with polymicrobial infection. For monomicrobial infection, bacteriological efficacy was higher in patients infected with gram-positive bacteria (48 of 53, 90.6%) than in patients infected with gram-negative bacteria (105 of 142, 73.9%). The MIC80 of GPFX was 0.39 μg/ml in 115 strains of causative organisms in which the MIC80 was determined in RTI, and the MIC80 of norfloxacin (NFLX), ofloxacin (0FLX), enoxacin (ENX) and ciprofloxacin (CPFX) were 6.25, 1.56, 6.25 and 0.78 μg/ml, respectively, in 97 strains. Adverse drug reactions were observed in 26 (5.0%, 38 cases) of 519 patients, including mostly gastrointestinal symptoms, CNS symptoms and hypersensitive symptoms. Abnormal clinical laboratory test values were observed in 49 (10.0%) of 490 patients. Major changes included increased eosinophil and transaminase. None of the reported symptoms or abnormal changes were serious. Based on clinical efficacy, adverse drug reactions and abnormal clinical laboratory test values, GPFX was judged to be useful in 432 (84.7%) of a total of 510 patients, 422 (84.9%) of 497 with RTI and 10 (76.9%) of 13 with UTI. From these results, GPFX was considered to be useful in the treatment of various infectious diseases, particularly RTI, in the field of internal medicine.",

author = "Hiroyuki Kobayashi and Hiroaki Takeda and Hidehiro Watanabe and Hiroshi Ohtami and Susumu Sakayori and Akira Saito and Ichiro Nakayama and Kiyoshi Sato and Masumi Tomizawa and Yohmei Hiraga and Mitsuhide Ohmichi and Kazuo Takebe and Seiichi Murakami and Mitsuo Masuda and Kenichi Imamura and Hisashi Nakahata and Miyoko Saito and Takeshi Osonoi and Masashi Tamura and Kazuki Konishi and Kazuo Obara and Taro Chiba and Yoji Aoyama and Akiko Shiba and Akira Watanabe and Kazunao Niizuma and Shigeo Takizawa and Yushi Nakai and Yoshihiro Honda and Masataka Katsu and Akira Ohishi and Morio Nakamura and Kotaro Kaneko and Michihiro Sakauchi and Noboru Aosaki and Kaoru Shimada and Hajime Goto and Mieko Goto and Yasuyuki Sano and Yasufumi Miyamoto and Yasuo Arai and Norio Kikuchi and Osamu Sakai and Koya Shiba and Masaki Yoshida and Seiji Hori and Jingoro Shimada and Kihachiro Shimizu and Koichiro Nakata and Tatsuo Nakatani and Eiyasu Tsuboi and Koji Narui and Yoshitaka Nakamori and Hiroko Inagawa and Kyoichi Totsuka and Yusuke Shibata and Ken Kikuchi and Hiromi Hasegawa and Takeshi Mori and Hiroshi Isonuma and Mayumi Takahashi and Tsukasa Ebe and Masayoshi Inagaki and Otohiko Kunii and Atsuko Guji and Isao Ohyatsu and Yasuo Ono and Taku Miyashita and Hajime Nishiya and Yasumasa Tokumura and Hajime Sugiyama and Morimichi Yamaguchi and Masumi Aoki and Toshiaki Haga and Hideo Miyashita and Yasuo Ikeda and Masahiro Kisaki and Shigehisa Mori and Hiroshi Uchida and Yoshio Kobayashi and Koichiro Kudo and Tadashi Horiuchi and Shunsuke Shoji and Junzaburo Kabe and Harumi Shishido and Hideaki Nagai and Koji Satoh and Atsuyuki Kurashima and Shuji Miyake and Kenji Kawakami and Koji Hayashi and Fumio Matumoto and Takeo Imai and Iwao Sakurai and Koji Yoshikawa and Takayuki Takahashi and Masayuki Morita and Shigeki Odagiri and Kaneo Suzuki and Hiroshi Takahashi and Kenichi Takahashi and Takao Okubo and Hirotada Ikeda and Tamotsu Kaneko and Masaaki Arakawa and Nobuki Aoki and Osamu Sekine and Yasutoshi Suzuki and Katsuji Uno and Motohiro Yagi and Hajimu Takeda and Saburo Izumi and Atsuhiko Sato and Kingo Senda and Takafumi Suda and Ryoji Tamura and Atsushi Yoshitomi and Takeshi Yagi and Toshihiko Takeuchi and Yasuo Yamada and Atsushi Nakamura and Toshinobu Yamamoto and Kazuhide Yamamoto and Hidekazu Hanaki and Toshiyuki Yamamoto and Toru Matsuura and Masahiro Yamagoshi and Kanzo Suzuki and Kaoru Shimokata and Satoshi Ichiyama and Hidehiko Saito and Shuzo Sakai and Shiro Nomura and Kazuyoshi Senda and Takeshi Iwahara and Hironobu Minami and Masashi Yamamoto and Hiroshi Saito and Sadaaki Yamori and Tomohisa Shibagaki and Keisuke Nishiwaki and Kazuo Nakanishi and Nobuhiro Narita and Keiichi Mikasa and Masayoshi Sawaki and Mitsuru Konishi and Koichi Maeda and Kaoru Hamada and Shoji Takeuchi and Masahiro Sakamoto and Masayuki Tsujimoto and Mikikazu Kunimatsu and Fumiyuki Kuze and Mitsuru Kawai and Fumio Miki and Yoshiyasu Ikuno and Akihito Murata and Kazuo Sakamoto and Masato Hiruma and Shinichiro Otani and Yasushi Hara and Koji Nakayama and Satohiko Tanaka and Akihisa Hanatani and Saburo Yano and Masaru Nakagawa and Rinzo Soejima and Niro Okimoto and Osamu Moriya and Yoshihito Niki and Toshiharu Matsushima and Makoto Kimura and Yoshihiro Kobashi and Norifumi Adachi and Jun Tanabe and Yoshihiko Tano and Hiroki Hara and Michio Yamakido and Kenji Hasegawa and Tsuyoshi Ogura and Kanji Asada and Osamu Namikawa and Shinsuke Nishioka and Masahiko Azuma and Mikie Maeda and Minoru Shirakami and Yoshiyuki Niho and Yoshiro Sawae and Kaoru Okada and Koji Takaki and Nobuyuki Shimono and Hiroyasu Misumi and Katsuhiko Eguchi and Kotaro Oizumi and Naoto Tokunaga and Yoichiro Ichikawa and Takafumi Yano and Kohei Hara and Shigeru Kohno and Hironobu Koga and Mitsuo Kaku and Kazunori Tomono and Naomi Ito and Koichi Watanabe and Keizo Matsumoto and Masakazu Takasugi and Mikio Taguchi and Kazunori Oishi and Atsushi Takahashi and Hiroshi Watanabe and Akemi Omori and Kiwao Watanabe and Tsuyoshi Nagatake and Hirofumi Tanaka and Soichiro Yamauchi and Tomoku Ichimiya and Kazufumi Hirai and Hiroshi Kawano and Takayoshi Tashiro and Kiyoshi Shima and Shinobu Takenaka and Atsushi Saito and Hiroshi Fukuhara and Yuei Irabu and Jun Inadome and Nobuchika Kusano and Yoshiko Furugen and Isamu Nakasone and Shinko Taira",

year = "1995",

doi = "10.11250/chemotherapy1995.43.Supplement1_333",

language = "English",

volume = "43",

pages = "333--351",

journal = "Japanese Journal of Chemotherapy",

issn = "1340-7007",

publisher = "Japan Society of Chemotherapy",

}

TY - JOUR

T1 - Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine

AU - Kobayashi, Hiroyuki

AU - Takeda, Hiroaki

AU - Watanabe, Hidehiro

AU - Ohtami, Hiroshi

AU - Sakayori, Susumu

AU - Saito, Akira

AU - Nakayama, Ichiro

AU - Sato, Kiyoshi

AU - Tomizawa, Masumi

AU - Hiraga, Yohmei

AU - Ohmichi, Mitsuhide

AU - Takebe, Kazuo

AU - Murakami, Seiichi

AU - Masuda, Mitsuo

AU - Imamura, Kenichi

AU - Nakahata, Hisashi

AU - Saito, Miyoko

AU - Osonoi, Takeshi

AU - Tamura, Masashi

AU - Konishi, Kazuki

AU - Obara, Kazuo

AU - Chiba, Taro

AU - Aoyama, Yoji

AU - Shiba, Akiko

AU - Watanabe, Akira

AU - Niizuma, Kazunao

AU - Takizawa, Shigeo

AU - Nakai, Yushi

AU - Honda, Yoshihiro

AU - Katsu, Masataka

AU - Ohishi, Akira

AU - Nakamura, Morio

AU - Kaneko, Kotaro

AU - Sakauchi, Michihiro

AU - Aosaki, Noboru

AU - Shimada, Kaoru

AU - Goto, Hajime

AU - Goto, Mieko

AU - Sano, Yasuyuki

AU - Miyamoto, Yasufumi

AU - Arai, Yasuo

AU - Kikuchi, Norio

AU - Sakai, Osamu

AU - Shiba, Koya

AU - Yoshida, Masaki

AU - Hori, Seiji

AU - Shimada, Jingoro

AU - Shimizu, Kihachiro

AU - Nakata, Koichiro

AU - Nakatani, Tatsuo

AU - Tsuboi, Eiyasu

AU - Narui, Koji

AU - Nakamori, Yoshitaka

AU - Inagawa, Hiroko

AU - Totsuka, Kyoichi

AU - Shibata, Yusuke

AU - Kikuchi, Ken

AU - Hasegawa, Hiromi

AU - Mori, Takeshi

AU - Isonuma, Hiroshi

AU - Takahashi, Mayumi

AU - Ebe, Tsukasa

AU - Inagaki, Masayoshi

AU - Kunii, Otohiko

AU - Guji, Atsuko

AU - Ohyatsu, Isao

AU - Ono, Yasuo

AU - Miyashita, Taku

AU - Nishiya, Hajime

AU - Tokumura, Yasumasa

AU - Sugiyama, Hajime

AU - Yamaguchi, Morimichi

AU - Aoki, Masumi

AU - Haga, Toshiaki

AU - Miyashita, Hideo

AU - Ikeda, Yasuo

AU - Kisaki, Masahiro

AU - Mori, Shigehisa

AU - Uchida, Hiroshi

AU - Kobayashi, Yoshio

AU - Kudo, Koichiro

AU - Horiuchi, Tadashi

AU - Shoji, Shunsuke

AU - Kabe, Junzaburo

AU - Shishido, Harumi

AU - Nagai, Hideaki

AU - Satoh, Koji

AU - Kurashima, Atsuyuki

AU - Miyake, Shuji

AU - Kawakami, Kenji

AU - Hayashi, Koji

AU - Matumoto, Fumio

AU - Imai, Takeo

AU - Sakurai, Iwao

AU - Yoshikawa, Koji

AU - Takahashi, Takayuki

AU - Morita, Masayuki

AU - Odagiri, Shigeki

AU - Suzuki, Kaneo

AU - Takahashi, Hiroshi

AU - Takahashi, Kenichi

AU - Okubo, Takao

AU - Ikeda, Hirotada

AU - Kaneko, Tamotsu

AU - Arakawa, Masaaki

AU - Aoki, Nobuki

AU - Sekine, Osamu

AU - Suzuki, Yasutoshi

AU - Uno, Katsuji

AU - Yagi, Motohiro

AU - Takeda, Hajimu

AU - Izumi, Saburo

AU - Sato, Atsuhiko

AU - Senda, Kingo

AU - Suda, Takafumi

AU - Tamura, Ryoji

AU - Yoshitomi, Atsushi

AU - Yagi, Takeshi

AU - Takeuchi, Toshihiko

AU - Yamada, Yasuo

AU - Nakamura, Atsushi

AU - Yamamoto, Toshinobu

AU - Yamamoto, Kazuhide

AU - Hanaki, Hidekazu

AU - Yamamoto, Toshiyuki

AU - Matsuura, Toru

AU - Yamagoshi, Masahiro

AU - Suzuki, Kanzo

AU - Shimokata, Kaoru

AU - Ichiyama, Satoshi

AU - Saito, Hidehiko

AU - Sakai, Shuzo

AU - Nomura, Shiro

AU - Senda, Kazuyoshi

AU - Iwahara, Takeshi

AU - Minami, Hironobu

AU - Yamamoto, Masashi

AU - Saito, Hiroshi

AU - Yamori, Sadaaki

AU - Shibagaki, Tomohisa

AU - Nishiwaki, Keisuke

AU - Nakanishi, Kazuo

AU - Narita, Nobuhiro

AU - Mikasa, Keiichi

AU - Sawaki, Masayoshi

AU - Konishi, Mitsuru

AU - Maeda, Koichi

AU - Hamada, Kaoru

AU - Takeuchi, Shoji

AU - Sakamoto, Masahiro

AU - Tsujimoto, Masayuki

AU - Kunimatsu, Mikikazu

AU - Kuze, Fumiyuki

AU - Kawai, Mitsuru

AU - Miki, Fumio

AU - Ikuno, Yoshiyasu

AU - Murata, Akihito

AU - Sakamoto, Kazuo

AU - Hiruma, Masato

AU - Otani, Shinichiro

AU - Hara, Yasushi

AU - Nakayama, Koji

AU - Tanaka, Satohiko

AU - Hanatani, Akihisa

AU - Yano, Saburo

AU - Nakagawa, Masaru

AU - Soejima, Rinzo

AU - Okimoto, Niro

AU - Moriya, Osamu

AU - Niki, Yoshihito

AU - Matsushima, Toshiharu

AU - Kimura, Makoto

AU - Kobashi, Yoshihiro

AU - Adachi, Norifumi

AU - Tanabe, Jun

AU - Tano, Yoshihiko

AU - Hara, Hiroki

AU - Yamakido, Michio

AU - Hasegawa, Kenji

AU - Ogura, Tsuyoshi

AU - Asada, Kanji

AU - Namikawa, Osamu

AU - Nishioka, Shinsuke

AU - Azuma, Masahiko

AU - Maeda, Mikie

AU - Shirakami, Minoru

AU - Niho, Yoshiyuki

AU - Sawae, Yoshiro

AU - Okada, Kaoru

AU - Takaki, Koji

AU - Shimono, Nobuyuki

AU - Misumi, Hiroyasu

AU - Eguchi, Katsuhiko

AU - Oizumi, Kotaro

AU - Tokunaga, Naoto

AU - Ichikawa, Yoichiro

AU - Yano, Takafumi

AU - Hara, Kohei

AU - Kohno, Shigeru

AU - Koga, Hironobu

AU - Kaku, Mitsuo

AU - Tomono, Kazunori

AU - Ito, Naomi

AU - Watanabe, Koichi

AU - Matsumoto, Keizo

AU - Takasugi, Masakazu

AU - Taguchi, Mikio

AU - Oishi, Kazunori

AU - Takahashi, Atsushi

AU - Watanabe, Hiroshi

AU - Omori, Akemi

AU - Watanabe, Kiwao

AU - Nagatake, Tsuyoshi

AU - Tanaka, Hirofumi

AU - Yamauchi, Soichiro

AU - Ichimiya, Tomoku

AU - Hirai, Kazufumi

AU - Kawano, Hiroshi

AU - Tashiro, Takayoshi

AU - Shima, Kiyoshi

AU - Takenaka, Shinobu

AU - Saito, Atsushi

AU - Fukuhara, Hiroshi

AU - Irabu, Yuei

AU - Inadome, Jun

AU - Kusano, Nobuchika

AU - Furugen, Yoshiko

AU - Nakasone, Isamu

AU - Taira, Shinko

PY - 1995

Y1 - 1995

N2 - Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine. The clinical usefulness of grepafloxacin (GPFX), a new quinolone synthesized as an oral antibacterial agent, in various infections in the field of internal medicine was investigated by collaborative research at 62 institutions nationwide. GPFX was administered primarily to patients with respiratory tract infections (RTI), mostly at daily doses of 100~300 mg once or in 2 divided doses. Clinical efficacy was evaluated in 509 of a total of 525 patients for analysis and efficacy was observed in 443 (87.0%) of the 509, including 432 (87.1%) of 496 patients with RTI and 11 (84.6%) of 13 patients with urinary tract infections (UTI). In RTI by disease, clinical efficacy was observed in 19 (86.4%) of 22 patients with pharyngolaryngitis or pharyngitis, 17 (94.4%) of 18 with tonsillitis, 53 (91.4%) of 58 with acute bronchitis, 104 (87.4%) of 119 with pneumonia, 17 (89.5%) of 19 with mycoplasmal pneumonia, 5 (100%) of 5 with atypical pneumonia, 117 (87.3%) of 133 with chronic bronchitis, 48 of 63 with bronchiectasis, 17 (89.5%) of 19 with diffuse panbronchiolitis, and 35 (87.5%) of 40 with secondary infection with chronic respiratory disease. Bacteriological efficacy in RTI was evaluated in 233 patients. Bacteriological eradication was observed in 154 (78.2%) of 197 patients with monomicrobial infection and 22 (61.1%) of 36 with polymicrobial infection. For monomicrobial infection, bacteriological efficacy was higher in patients infected with gram-positive bacteria (48 of 53, 90.6%) than in patients infected with gram-negative bacteria (105 of 142, 73.9%). The MIC80 of GPFX was 0.39 μg/ml in 115 strains of causative organisms in which the MIC80 was determined in RTI, and the MIC80 of norfloxacin (NFLX), ofloxacin (0FLX), enoxacin (ENX) and ciprofloxacin (CPFX) were 6.25, 1.56, 6.25 and 0.78 μg/ml, respectively, in 97 strains. Adverse drug reactions were observed in 26 (5.0%, 38 cases) of 519 patients, including mostly gastrointestinal symptoms, CNS symptoms and hypersensitive symptoms. Abnormal clinical laboratory test values were observed in 49 (10.0%) of 490 patients. Major changes included increased eosinophil and transaminase. None of the reported symptoms or abnormal changes were serious. Based on clinical efficacy, adverse drug reactions and abnormal clinical laboratory test values, GPFX was judged to be useful in 432 (84.7%) of a total of 510 patients, 422 (84.9%) of 497 with RTI and 10 (76.9%) of 13 with UTI. From these results, GPFX was considered to be useful in the treatment of various infectious diseases, particularly RTI, in the field of internal medicine.

AB - Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine. The clinical usefulness of grepafloxacin (GPFX), a new quinolone synthesized as an oral antibacterial agent, in various infections in the field of internal medicine was investigated by collaborative research at 62 institutions nationwide. GPFX was administered primarily to patients with respiratory tract infections (RTI), mostly at daily doses of 100~300 mg once or in 2 divided doses. Clinical efficacy was evaluated in 509 of a total of 525 patients for analysis and efficacy was observed in 443 (87.0%) of the 509, including 432 (87.1%) of 496 patients with RTI and 11 (84.6%) of 13 patients with urinary tract infections (UTI). In RTI by disease, clinical efficacy was observed in 19 (86.4%) of 22 patients with pharyngolaryngitis or pharyngitis, 17 (94.4%) of 18 with tonsillitis, 53 (91.4%) of 58 with acute bronchitis, 104 (87.4%) of 119 with pneumonia, 17 (89.5%) of 19 with mycoplasmal pneumonia, 5 (100%) of 5 with atypical pneumonia, 117 (87.3%) of 133 with chronic bronchitis, 48 of 63 with bronchiectasis, 17 (89.5%) of 19 with diffuse panbronchiolitis, and 35 (87.5%) of 40 with secondary infection with chronic respiratory disease. Bacteriological efficacy in RTI was evaluated in 233 patients. Bacteriological eradication was observed in 154 (78.2%) of 197 patients with monomicrobial infection and 22 (61.1%) of 36 with polymicrobial infection. For monomicrobial infection, bacteriological efficacy was higher in patients infected with gram-positive bacteria (48 of 53, 90.6%) than in patients infected with gram-negative bacteria (105 of 142, 73.9%). The MIC80 of GPFX was 0.39 μg/ml in 115 strains of causative organisms in which the MIC80 was determined in RTI, and the MIC80 of norfloxacin (NFLX), ofloxacin (0FLX), enoxacin (ENX) and ciprofloxacin (CPFX) were 6.25, 1.56, 6.25 and 0.78 μg/ml, respectively, in 97 strains. Adverse drug reactions were observed in 26 (5.0%, 38 cases) of 519 patients, including mostly gastrointestinal symptoms, CNS symptoms and hypersensitive symptoms. Abnormal clinical laboratory test values were observed in 49 (10.0%) of 490 patients. Major changes included increased eosinophil and transaminase. None of the reported symptoms or abnormal changes were serious. Based on clinical efficacy, adverse drug reactions and abnormal clinical laboratory test values, GPFX was judged to be useful in 432 (84.7%) of a total of 510 patients, 422 (84.9%) of 497 with RTI and 10 (76.9%) of 13 with UTI. From these results, GPFX was considered to be useful in the treatment of various infectious diseases, particularly RTI, in the field of internal medicine.

UR - http://www.scopus.com/inward/record.url?scp=0029101342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029101342&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1995.43.Supplement1_333

DO - 10.11250/chemotherapy1995.43.Supplement1_333

M3 - Article

AN - SCOPUS:0029101342

SN - 1340-7007

VL - 43

SP - 333

EP - 351

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

ER -

Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this